Hormonal Contraception Market By Hormone 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Hormonal Contraception Market
Hormonal Contraception Market: By Hormone (Androgens, Estrogens, Progestrogens, Gonadotropins, Antiandrogens); By Method (Combined Oral, Oral Pill, Implanted, Injected, Others); By End-User (Hospital, Clinics, Others) and By Region-Forecast (2016-2021)
Report Code : HCR 0221
Updated Date: 03 March, 2016   20% discount on this report

  • Report Description
  • Table of Contents
  • Customization Options
Hormonal contraception is a birth control method that acts on the endocrine system. Several types of female hormones are used to prevent ovulation and avoid fertilization. Hormonal contraception also results in changes in the uterus making it unlikely to develop pregnancy.

Globally, an increase in adoption of hormonal contraception for birth control, rise in female population on a global level and implementation of temporary and low cost contraceptive practices instead of permanent contraception are the prime growth drivers of hormonal contraception. The major opportunities for the growth of this market are urbanization and increased consciousness about hormonal contraception and the policies setup by the governments to promote hormonal contraception. However, adverse side effects related to the use of hormonal contraceptives is the key restraint for the hormonal contraception market.

This report identifies the global hormonal contraception market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to hormonal contraception market.
 
Hormonal Contraception Market

Geographically, Asia Pacific dominates the hormonal contraception market, and is projected to have the fastest growth, owing to growing population in this region on a global level.

This report segments hormonal contraception market on the basis of hormone, by method, by end-use and regional market as follows:
  • Hormonal Contraception  Market, by hormone: Androgens, Estrogens, Progestrogens, Gonadotropins and Antiandrogens
  • Hormonal Contraception  Market, by method: Combined Oral, Oral Pill, Implanted, Injected, Intrauterine and Transdermal Patch
  • Hormonal Contraception Market, by end-use: Hospital, Clinics, Gynaecology Centers and Others
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico.

This report identifies all the major companies operating in the hormonal contraception market. Some of the major companies’ profiles in detail are as follows:
  • Bayer Pharma AG
  • Merck & Co., Inc.
  • Agile Therapeutics, Inc.
  • Teva Pharmaceutical Industries Limited
  • Lupin Pharmaceuticals, Inc.
1. Hormonal Contraception  Market –Overview
2. Executive Summary
3. 
Hormonal Contraception Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Hormonal Contraception  Market–Forces
   4.1. Drivers
      4.1.1. Increase in adoption of hormonal contraception for birth control
      4.1.2. Rise in female population on a global level
      4.1.3. Implementation of temporary and low cost contraceptive practices instead of permanent contraception
   4.2. Restraints
      4.2.1. Adverse side effects related to the use of hormonal contraceptives
   4.3. Opportunities
      4.3.1. Urbanization and increased consciousness about hormonal contraception
      4.3.2. Policies setup by the governments to promote hormonal contraception
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Hormonal Contraception  Market, By Hormone
   5.1. Androgens
   5.2. Estrogens
   5.3. Progestrogens
   5.4. Gonadotropins and
   5.5. Antiandrogens
6. Hormonal Contraception  Market, By Method
   6.1. Combined Oral
   6.2. Oral Pill
   6.3. Implanted
   6.4. Injected
   6.5. Intrauterine and
   6.6. Transdermal Patch
7. Hormonal Contraception Market, By End-Use
   7.1. Hospital
   7.2. Clinics
   7.3. Gynaecology Centers
   7.4. Others
8. Hormonal Contraception  Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Hormonal Contraception  – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   10.1. Bayer Pharma AG
   10.2. Merck & Co., Inc.
   10.3. Pfizer, Inc.
   10.4. Agile Therapeutics, Inc.
   10.5. Teva Pharmaceutical Industries Limited
   10.6. Amgen
   10.7. Cipla Ltd.
   10.8. Glenmark Pharmaceuticals
   10.9. Lupin Pharmaceuticals, Inc.
   10.10. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll